Journal
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
Volume 97, Issue 11, Pages 1526-1547Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/09553002.2021.1969054
Keywords
Animal models; animal rule; countermeasures; cytokines; food and drug administration; growth factors; irradiation
Funding
- Armed Forces Radiobiology Research Institute/Uniformed Services University of the Health Sciences [RBB21103720]
Ask authors/readers for more resources
This article reports on the status of pharmaceuticals in late stage development for treating acute injuries caused by radiological/nuclear exposures. Four medications have been deemed safe and effective by the US FDA for hematopoietic acute radiation syndrome (H-ARS), primarily recombinant growth factors. Additional medications are needed for other sub-syndromes of ARS, potentially through a polypharmaceutical or bioengineered approach.
Purpose The intent of this article is to report the status of some of the pharmaceuticals currently in late stage development for possible use for individuals unwantedly and acutely injured as a result of radiological/nuclear exposures. The two major questions we attempt to address here are: (a) What medicinals are currently deemed by regulatory authorities (US FDA) to be safe and effective and are being stockpiled? (b) What additional agents might be needed to make the federal/state/local medicinal repositories more robust and useful in effectively managing contingencies involving radiation overexposures? Conclusions A limited number (precisely four) of medicinals have been deemed safe and effective, and are approved by the US FDA for the 'hematopoietic acute radiation syndrome (H-ARS).' These agents are largely recombinant growth factors (e.g. rhuG-CSF/filgrastim, rhuGM-CSF/sargramostim) that target and stimulate myeloid progenitors within bone marrow. Romiplostim, a small molecular agonist that enhances platelet production via stimulation of bone marrow megakaryocytes, has been recently approved and indicated for H-ARS. It is critical that additional agents for other major sub-syndromes of ARS (gastrointestinal-ARS) be approved. Future success in developing such medicinals will undoubtedly entail some form of a polypharmaceutical strategy, or perhaps novel, bioengineered chimeric agents with multiple, radioprotective/radiomitigative functionalities.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available